Bruce Booth Sells 6,101 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 6,101 shares of Kymera Therapeutics stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $91.23, for a total value of $556,594.23. Following the sale, the director owned 685,501 shares of the company’s stock, valued at approximately $62,538,256.23. This represents a 0.88% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Bruce Booth also recently made the following trade(s):

• On Friday, December 12th, Bruce Booth sold 678 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.04, for a total transaction of $61,725.12.
• On Wednesday, December 10th, Bruce Booth sold 229,809 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.73, for a total transaction of $21,080,379.57.

Kymera Therapeutics Stock Performance

Shares of KYMR opened at $89.68 on Friday. Kymera Therapeutics, Inc. has a fifty-two week low of $19.44 and a fifty-two week high of $103.00. The company has a market capitalization of $6.45 billion, a PE ratio of -24.98 and a beta of 2.28. The stock has a fifty day moving average of $64.77 and a two-hundred day moving average of $52.02.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Tuesday, November 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.19). Kymera Therapeutics had a negative net margin of 674.81% and a negative return on equity of 32.92%. The company had revenue of $2.76 million during the quarter, compared to analysts’ expectations of $23.15 million. As a group, equities research analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Several hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in shares of Kymera Therapeutics by 7.0% in the first quarter. Vanguard Group Inc. now owns 5,231,392 shares of the company’s stock valued at $143,183,000 after purchasing an additional 344,080 shares during the period. Invesco Ltd. grew its holdings in Kymera Therapeutics by 36.9% in the 1st quarter. Invesco Ltd. now owns 42,075 shares of the company’s stock worth $1,152,000 after buying an additional 11,343 shares in the last quarter. Nuveen LLC acquired a new stake in Kymera Therapeutics in the 1st quarter valued at approximately $3,920,000. Russell Investments Group Ltd. raised its stake in Kymera Therapeutics by 40.0% during the 1st quarter. Russell Investments Group Ltd. now owns 82,507 shares of the company’s stock valued at $2,258,000 after acquiring an additional 23,584 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics during the 1st quarter valued at $68,000.

Analyst Upgrades and Downgrades

KYMR has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price objective on shares of Kymera Therapeutics from $70.00 to $125.00 and gave the company an “overweight” rating in a research report on Wednesday. UBS Group raised shares of Kymera Therapeutics to a “strong-buy” rating in a report on Thursday, December 4th. HC Wainwright lifted their price target on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley upped their price objective on shares of Kymera Therapeutics from $73.00 to $127.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Citigroup lifted their target price on Kymera Therapeutics from $80.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Kymera Therapeutics currently has an average rating of “Buy” and a consensus price target of $112.80.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.